Who are rFVIII (BAY81-8973) on demand's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): rFVIIIFc, ReFacto, Plasma-derived FVIII/VWF concentrate, OBIZUR, Traditional Cryoprecipitate, Afstyla®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rfviii-bay81-8973-on-demand.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

rFVIII (BAY81-8973) on demand — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

rFVIII (BAY81-8973) on demand (rFVIII (BAY81-8973) on demand) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: recombinant factor VIII replacement therapy. Area: Hematology.

phase 3 recombinant factor VIII replacement therapy Factor VIII Hematology Biologic Live · refreshed every 30 min

Target snapshot

rFVIII (BAY81-8973) on demand (rFVIII (BAY81-8973) on demand) — Bayer. rFVIII (BAY81-8973) is a recombinant factor VIII replacement therapy that mimics the natural protein to treat bleeding episodes in patients with hemophilia A.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
rFVIII (BAY81-8973) on demand TARGET	rFVIII (BAY81-8973) on demand	Bayer	phase 3	recombinant factor VIII replacement therapy	Factor VIII
rFVIIIFc	rFVIIIFc	Bioverativ Therapeutics Inc.	marketed	Recombinant clotting factor (Factor VIII replacement therapy)	Factor VIII / FcRn (neonatal Fc receptor)
ReFacto	ReFacto	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Recombinant clotting factor	Factor VIII (antihemophilic factor)
Plasma-derived FVIII/VWF concentrate	Plasma-derived FVIII/VWF concentrate	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	marketed	Coagulation factor concentrate	Factor VIII and von Willebrand Factor
OBIZUR	OBIZUR	Baxalta now part of Shire	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
Traditional Cryoprecipitate	Traditional Cryoprecipitate	Weill Medical College of Cornell University	marketed	Blood product; clotting factor concentrate	Fibrinogen, Factor VIII, von Willebrand factor, Fibronectin, Factor XIII
Afstyla®	Afstyla®	CSL Behring	marketed	Recombinant clotting factor VIII	Factor VIII (coagulation factor VIII)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (recombinant factor VIII replacement therapy class)

Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rFVIII (BAY81-8973) on demand — Competitive Intelligence Brief. https://druglandscape.com/ci/rfviii-bay81-8973-on-demand. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab